Financial Time (Free subscription) | yesterday
Biotech company Alizyme suffered another blow yesterday as its share price halved after disappointing trial results. Its shares fell 49.9 per cent to a record...
The Irish Times (Free subscription) | 07/23/2008
A DRUG which significantly shrank tumours in 21 men with advanced prostate cancer could provide new hope to patients with this form of the disease.
Medical News Today (Free subscription) | 07/22/2008
A new trial drug called abiraterone has shown a high success rate at treating men with an aggressive, drug resistant, and often fatal form of prostate cancer. 70 to 80 per cent of the men on the trial experienced dramatic reductions in PSA (a protein marker for prostate cancer) and tumour shrinkage, even in tumours that had spread to bone and other tissue.
The Guardian (Free subscription) | 07/22/2008
New treatment could allow sufferers to work and travel and potentially save lives, say researchers
The Guardian (Free subscription) | 07/22/2008
Drug could put thousands of men into remission and potentially save lives, worldwide clinical trial finds
Medical News Today (Free subscription) | 07/21/2008
A new study published in The Lancet has some promising results for treating Alzheimer's disease (AD) with the drug dimebon. Researchers show that in patients with mild-to-moderate AD, dimebon significantly improves the clinical course of the disease. Unlike any other approved AD therapy, dimebon resulted in increasing benefits over a 12 month period.
Medical News Today (Free subscription) | 07/21/2008
Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant...
Medical News Today (Free subscription) | 07/19/2008
A new survey reveals that while 82 percent of men with erectile dysfunction (ED) surveyed recognize it as an indicator of other health conditions, such as heart disease and diabetes, nearly 40 percent have never discussed the condition with their doctors.
Kentucky Law Review (Free subscription) | 07/19/2008
Prosecutors pursuing a superseding indictment of more charges in diet drug case in story from Herald Leader: Fen-phen attorneys could face more charges COVINGTON . A federal judge has set an October trial date for two Lexington-area lawyers accused of pocketing millions of dollars that should have gone to their former clients in a diet-drug settlement. But an Oct. 14 start for the second criminal trial...
Bitch News (Free subscription) | 07/18/2008
Alzheimer’s drug trial ‘promise’ , BBC News reports here: A drug once used to treat hayfever “significantly improves” symptoms in patients with mild to moderate Alzheimer’s disease, research suggests.
Kentucky Law Review (Free subscription) | 07/18/2008
New trial date set in fen-phen case HERALD LEADER A federal judge has set Oct. 14 as the start of a retrial for two Lexington lawyers charged in a diet drug settlement case. The Lexington Herald-Leader reported the retrial will likely be pushed back after federal prosecutors said at a court hearing Wednesday that they might seek additional charges against attorneys William Gallion and Shirley Cunningham...
BBC News (Free subscription) | 07/18/2008
A drug once used to treat hayfever "improves" symptoms in patients with Alzheimer's disease, research suggests.
Market Watch (Free subscription) | 07/16/2008
TEL AVIV (MarketWatch) - Israeli stocks were mixed on Wednesday, with technology defying a broader-market drop, Israel Chemicals slumping, and investors continuing to punch out the real-estate companies.
Medical News Today (Free subscription) | 07/16/2008
Using community-based health advocates, delivering information within same-gender groups or adapting dietary and lifestyle advice to fit a particular community's likely diet can help people with type 2 diabetes control their blood sugar levels, certainly for up to six months, following health education. This conclusion was reached by a team of Cochrane Researchers after they considered the data in...
Market Watch (Free subscription) | 07/16/2008
TEL AVIV (MarketWatch) -- Teva Pharmaceutical Industries Ltd., the Jerusalem drugmaker, and Active Biotech AB, the Lund, Sweden, biotechnology company, said they're enrolling patients in a second Phase III trial of laquinimod, a treatment taken by mouth for relapsing-remitting multiple sclerosis. The first trial, called Bravo, began enrolling patients in April and aims to enroll 1,200; the second...
